首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique
【24h】

Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique

机译:LC-MS / MS方法在使用QconCAT技术同时定量人类肠道转运蛋白绝对丰度中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Transporter proteins expressed in the gastrointestinal tract play a major role in the oral absorption of some drugs, and their involvement may lead to drug-drug interaction (DDI) susceptibility when given in combination with drugs known to inhibit gut wall transporters. Anticipating such liabilities and predicting the magnitude of the impact of transporter proteins on oral drug absorption and DDIs requires quantification of their expression in human intestine, and linking these to data obtained through in vitro experiments. A quantitative targeted absolute proteomic method employing liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) together with a quantitative concatenation (QconCAT) strategy to provide proteotypic peptide standards has been applied to quantify ATP1A1 (sodium/potassium-ATPase; Na/K-ATPase), CDH17 (human peptide transporter 1; HPT1), ABCB1 (P-glycoprotein; P-gp), ABCG2 (breast cancer resistance protein; BCRP), ABCC2 (multidrug resistance-associated protein 2; MRP2) and SLC51A (Organic Solute Transporter subunit alpha; OST-alpha), in human distal jejunum (n = 3) and distal ileum (n = 1) enterocyte membranes. Previously developed selected reaction monitoring (SRM) schedules were optimised to enable quantification of the proteotypic peptides for each transporter. After harvesting enterocytes by calcium chelation elution and generating a total membrane fraction, the proteins were subjected to proteolytic digestion. To account for losses of peptides during the digestion procedure, a gravimetric method is also presented. The linearity of quantifying the QconCAT from an internal standard (correlation coefficient, R-2 = 0.998) and quantification of all target peptides in a pooled intestinal quality control sample (R-2 >= 0.980) was established. The assay was also assessed for within and between-day precision, demonstrating a <15% coefficient of variation for all peptides across 3 separate analytical runs, over 2 days. The methods were applied to obtain the absolute abundances for all targeted proteins. In all samples, Na/K-ATPase, HPT1, P-gp and BCRP were detected above the lower limit of quantitation (i.e., >0.2 fmol/mu g membrane protein). MRP2 abundance could be quantified in distal jejunum but not in the distal ileum sample. OST-alpha was not detected in 2 out of 3 jejunum samples. This study highlights the utility of a QconCAT strategy to quantify absolute transporter abundances in human intestinal tissues. (C) 2015 The Authors. Published by Elsevier B.V.
机译:在胃肠道中表达的转运蛋白在某些药物的口服吸收中起主要作用,当与已知抑制肠壁转运蛋白的药物联合使用时,它们的参与可能导致药物-药物相互作用(DDI)敏感性。预测此类责任并预测转运蛋白对口服药物吸收和DDI的影响程度,需要量化它们在人肠中的表达,并将其与通过体外实验获得的数据联系起来。采用液相色谱-串联质谱(LC-MS / MS)结合定量串联(QconCAT)策略提供蛋白质型肽标准品的定量靶向绝对蛋白质组学方法已用于定量ATP1A1(钠/钾-ATPase; Na / K-ATPase),CDH17(人多肽转运蛋白1; HPT1),ABCB1(P糖蛋白; P-gp),ABCG2(乳腺癌耐药蛋白; BCRP),ABCC2(多药耐药相关蛋白2; MRP2)和SLC51A(在人空肠远端(n = 3)和回肠远端(n = 1)肠细胞膜中的有机溶质转运蛋白亚基(OST-alpha)。优化了先前开发的选定反应监测(SRM)计划,以能够量化每种转运蛋白的蛋白型肽。通过钙螯合洗脱收获肠上皮细胞并产生总膜级分后,将蛋白质进行蛋白水解消化。为了解决消化过程中肽的损失,还提出了一种重量分析法。建立了从内标物定量QconCAT(相关系数,R-2 = 0.998)和在合并的肠质控样品(R-2> = 0.980)中所有目标肽的定量线性。还评估了该测定法的日内和日间精密度,表明在2天中的3次独立分析运行中,所有肽的变异系数均<15%。应用该方法获得所有目标蛋白的绝对丰度。在所有样品中,检测到的Na / K-ATPase,HPT1,P-gp和BCRP均高于定量下限(即> 0.2 fmol /μg膜蛋白)。 MRP2丰度可以在空肠远端定量,但不能在回肠远端样本中定量。在3个空肠样品中有2个未检测到OST-alpha。这项研究强调了QconCAT策略在量化人体肠道组织中绝对转运蛋白丰度方面的实用性。 (C)2015作者。由Elsevier B.V.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号